Emricasan: Phase IIb started

Conatus began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate 25 mg oral emricasan twice daily for 24 months in about 60 post-orthotopic liver transplant patients with reestablished liver fibrosis post-transplant due to recurrent HCV infection who have achieved a sustained viral response (SVR) following HCV antiviral therapy. ...